Jun Watanabe

The paper identifies and characterizes FCD-11, a first-in-class COMPASS inhibitor that reduces tumor size and extends survival in breast cancer models.

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.